Form 8-K BIOMARIN PHARMACEUTICAL For: Jan 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
BioMarin expects $3.2 billion in 2025 revenue, ROCTAVIAN write-down
January 12, 2026 4:46 PM ESTBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) disclosed preliminary financial results during a presentation at the J.P. Morgan Healthcare Conference on January 12, 2026.
The company estimates it generated approximately $3.2 billion in total revenues for 2025, based on unaudited preliminary results. VOXZOGO sales contributed approximately $920 million... More
